ATL names new division SonoSight

Article

ATL Ultrasound has announced that the distribution date for its handheld division took place on April 6 (SCAN 3/18/98). The new company, called SonoSight, will trade on the NASDAQ National Market under the ticker symbol SONO. ATL Ultrasound

ATL Ultrasound has announced that the distribution date for its handheld division took place on April 6 (SCAN 3/18/98). The new company, called SonoSight, will trade on the NASDAQ National Market under the ticker symbol SONO. ATL Ultrasound shareholders of record on March 30 will receive one share of SonoSight for every three shares held of ATL.

SonoSight has filed a 510(k) premarket notification for its first product, with commercial launch anticipated in 1999, according to ATL. A prototype of the first handheld system, targeted for use in women's healthcare, is expected within a few months. Other models are being developed for internal and emergency medical use.

In other SonoSight developments, Kevin Goodwin has been tapped as president and CEO of the company, with Kirby Cramer serving as chairman. Cramer is a member of the ATL board of directors and president of investment firm Keystone Capital Company.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.